First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Neoplasm Malignant Clinical Trial

Official title:

An Open-label, First-in-human, Single Agent, Dose Escalation Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR442257 in Patients With Relapsed and Refractory Multiple Myeloma and Relapsed and Refractory Non-Hodgkin Lymphoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04401020
• Other study ID #: TED16364
• Secondary ID: U1111-1244-25112
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: July 24, 2020
• Est. completion date: August 14, 2024

Study information

• Verified date: May 2024
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Primary Objective:

To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and relapsed and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recommended Phase 2 dose (RP2D)

Secondary Objectives:

• To characterize the safety profile of SAR442257

• To characterize the pharmacokinetics (PK) profile of SAR442257

• To assess preliminary evidence of antitumor activity

Description:

Study duration per participant is 2 months to estimated 16 months. Cycle lengths in this study are 27 days in Cycle 1 and 28 days for subsequent cycles as determined by totality of data collected thus far including PK/Pharmacodynamics (PD), safety and preliminary efficacy.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 47
• Est. completion date: August 14, 2024
• Est. primary completion date: March 2, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria :

Participant must be at least 18 years of age or of the country's legal age of majority if the legal age is >18 years old, at the time of signing the informed consent.

Life expectancy of at least 12 weeks. Eastern Cooperative Oncology Group (ECOG) performance status =2.

RRMM patients:

must have received at least 3 prior lines of therapy including proteasome inhibitor (PI), immunomodulatory agent (IMiD), and anti-CD38 mAb;

and must be refractory to anti-CD38 antibody (eg, daratumumab or isatuximab), characterized by progression within 60 days of the last dose of anti-CD38, regardless of which line it was given; and must be either relapsed or refractory to all established therapies with known clinical benefit in RRMM where approved and available, or are intolerant to those established therapies; based upon investigator's clinical judgement.

and must not be candidates for regimens known to provide clinical benefit based upon investigator's clinical judgement.

Patients with RRMM must have measurable disease as per the following:

• Serum M protein =0.5 g/dL (=5 g/L), or

• Urine M protein =200 mg/24 hours, or

• Serum free light chain (FLC) assay: involved FLC assay =10 mg/dL and an abnormal serum FLC ratio (<0.26 or >1.65).

Patients with RR-NHL must be relapsed or refractory to all established therapies with known clinical benefit where approved and available, or are intolerant to those established therapies; based upon investigator's clinical judgement.

Patients with RR-NHL must have measurable disease of at least one lesion =1.5 cm as documented by computed tomography (CT) scan, including the following subtype of disease:

• Diffuse large B-cell lymphoma (DLBCL).

• HGBCL with MYC and/or BCL2 and/or BCL6 rearrangement or HGBCL NOS,

• transformed follicular lymphoma (tFL),

• follicular lymphoma (FL),

• mantle cell lymphoma (MCL),

• marginal zone lymphoma (MZL),

• lymphoplasmacytic lymphoma,

• small lymphocytic lymphoma (SLL). Patients with RR-NHL subtype T cell lymphoma (TCL) including the following subtype of disease: Nodal peripheral TCL including angio-immunoblastic TCL (AITL), anaplastic large cell lymphoma (ALCL), adult T cell leukemia-lymphoma, and peripheral TCL NOS (not otherwise specified). Peripheral TCL of the innate immune system: breast implant ALCL, extranodal NK/TCL, enteropathy associated TCL, monomorphic epitheliotropic intestinal TCL, and hepatosplenic TCL. histopathologically confirmed mycosis fungoides or Sézary syndrome (cutaneous T cell lymphoma [CTCL] stage IIB or greater according to the European Organization for Research and Treatment of Cancer/International Society for Cutaneous Lymphomas [EORTC-ISCL] consensus classification) at study entry with progressive, persistent, or recurrent disease who have no available remaining standard therapeutic options (ie, refractory) as determined by the Investigator.

Patients with lymphoma must have availability of lymphoma tissue for biomarker testing:

either archived tissue or a fresh biopsy as a part of screening. On-treatment biopsy (Cycle 2 or beyond) is also expected if disease location is in a superficial lymph node. For post-CAR-T patients a fresh LN biopsy is expected if in a superficial node. For these patients tissue materials should be made available for analysis during the study. Excisional biopsy or resected tissue is required if clinically feasible; otherwise, core needle biopsy is acceptable. Fine needle aspirates are not acceptable.

Patients with lymphoma must have a =50% left ventricular ejection fraction (LVEF) and no pericardial effusion, as measured by echocardiogram (ECHO).

Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria:

Diagnosed or treated for another malignancy within 3 years prior to enrollment, except for basal cell carcinoma or squamous cell carcinoma of the skin, an in-situ malignancy, superficial bladder carcinoma or low risk prostate cancer.

Amyloidosis, chronic lymphocytic leukemia and prolymphocytic leukemia. Known central nervous system (CNS) involvement by myeloma, lymphoma or other CNS disease such as neurodegenerative condition or CNS movement disorder.

Has congestive heart failure (New York Heart Association) Grade =II; cardiomyopathy, active ischemia, or any other uncontrolled cardiac condition such as angina pectoris, clinically significant arrhythmia requiring therapy including anticoagulants, or clinically significant uncontrolled hypertension, QT interval corrected by the Fridericia method >480 msec (Grade =2). Acute myocardial infarction within 6 months before start of study treatment.

Has active autoimmune disease including autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, inflammatory bowel syndrome, pneumonitis or any chronic condition requiring a higher corticosteroid systemic equivalent than prednisone 10 mg daily.

Clinically-not controlled chronic or ongoing infectious disease requiring treatment at the time of first dose or within the 14 days before first dose.

Active hepatitis A, B, and C as defined below: active hepatitis A (defined as positive IgM), active hepatitis B (defined as either positive hepatitis B surface antigen or positive hepatitis B viral DNA test above the lower limit of detection of the assay, and hepatitis B core antibodies), or C infection (defined as a known positive hepatitis C antibody result and known quantitative hepatitis C [HCV] ribonucleic acid [RNA] results greater than the lower limits of detection of the assay).

Known positivity for Human Immunodeficiency Virus (HIV). Unresolved toxicities from prior anticancer therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade 1 or to levels dictated in the eligibility criteria with the exception of Grade 1 peripheral neuropathy, alopecia or toxicities from prior anticancer therapy that are considered irreversible (defined as having been present and stable for >4 weeks) which may be allowed if they are not otherwise described in the exclusion criteria.

Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.

Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Neoplasm Malignant
• Neoplasms

Intervention

Drug:
• SAR442257
Pharmaceutical form: Sterile powder for reconstitution Route of administration: Intravenous infusion

Locations

Country	Name	City	State
Czechia	Investigational Site Number : 2030003	Brno
Czechia	Investigational Site Number : 2030001	Ostrava - Poruba
Czechia	Investigational Site Number : 2030002	Praha 2
Korea, Republic of	Investigational Site Number : 4100001	Seoul	Seoul-teukbyeolsi
Korea, Republic of	Investigational Site Number : 4100002	Seoul	Seoul-teukbyeolsi
Norway	Investigational Site Number : 5780001	Oslo
Norway	Investigational Site Number : 5780101	Oslo
Spain	Investigational Site Number : 7240003	Badalona	Catalunya [Cataluña]
Spain	Investigational Site Number : 7240006	Madrid	Madrid, Comunidad De
Spain	Investigational Site Number : 7240007	Madrid
Spain	Investigational Site Number : 7240001	Pamplona	Navarra
Spain	Investigational Site Number : 7240005	Santander	Cantabria
Spain	Investigational Site Number : 7240004	Valencia
United States	City of Hope Site Number : 8400001	Duarte	California
United States	University of Miami - Sylvester Comprehensive Cancer Center Site Number : 8400005	Miami	Florida
United States	Mayo Clinic of Rochester Site Number : 8400003	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  Czechia,  Korea, Republic of,  Norway,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine maximum tolerated dose (MTD)	MTD: defined as the highest dose level (DL) with highest probability of Investigational Medicinal Product (IMP)-related dose limiting toxicity (DLT) rate within the target range (16 to 33%) among dose levels with less than 0.25 probability of DLT rate above target (>33%)	Baseline to estimated 4 weeks
Primary	Determine recommended Phase 2 dose (RP2D)	RP2D: defined as the dose selected for the further single agent testing in the future study	Baseline to estimated 4 months
Secondary	Number of participants with AEs/SAEs/AESI	Incidence of treatment-emergent adverse events (AEs)/serious adverse events (SAEs)/ adverse events of special interest (AESIs) and laboratory abnormalities	Baseline to 30 days after end of treatment
Secondary	Assessment of pharmacokinetic (PK) parameter: Cmax	Maximum concentration observed (Cmax)	through study completion (estimated 16 months)
Secondary	Assessment of PK parameter: Ctrough	Concentration observed just before treatment administration during repeated dosing (Ctrough)	through study completion (estimated 16 months)
Secondary	Assessment of PK parameter: AUC0-t	Area under the concentration versus time curve during a dosing interval (T) (AUC0-t)	up to 4 weeks
Secondary	Overall response rate for RRMM	Overall response rate will be assessed using the International Myeloma Working Group (IMWG) 2016 criteria for patients with RRMM	Baseline to 6 months
Secondary	Overall response rate for RR-NHL	Overall response rate will be assessed using the Response evaluation criteria in lymphoma (RECIL) 2017 criteria for patients with RR-NHL	Baseline to 6 months